Stem cell based gene therapy in prostate cancer.

Area of Science:

• Oncology
• Gene Therapy
• Stem Cell Biology

Background:

• Current prostate cancer treatments, particularly for hormone-refractory cases, often involve cytotoxic agents with significant adverse effects.
• Classic suicide gene therapy, while targeting cancer cells, can cause immune compromise due to viral vectors.

Purpose of the Study:

• To review the mechanisms and limitations of stem cell-based suicide gene therapy for prostate cancer.
• To explore stem cells as advanced cellular vectors for targeted cancer treatment.

Main Methods:

• Review of existing literature on stem cell-mediated gene therapy for prostate cancer.
• Analysis of various prodrug systems employed with stem cells, including cytosine deaminase/5-fluorocytosine and herpes simplex virus thymidine kinase/ganciclovir.

Main Results:

• Stem cells, particularly mesenchymal and neural stem cells, exhibit homing effects beneficial for targeted cancer therapy.
• Stem cell-based suicide gene therapy activates prodrugs within the tumor mass, reducing systemic toxicity and potentially eliminating resistant cancer cells and therapeutic stem cells.

Conclusions:

• Genetically engineered stem cells represent a promising and safer platform for prostate cancer gene therapy.
• Further research is needed to fully elucidate the mechanisms and overcome the limitations of stem cell-based approaches in prostate cancer treatment.